IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A treatment protocol that enables patients to have continued access to IPI-926.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Infinity Pharmaceuticals, Inc.
• Treatments: Veratrum Alkaloids

Criteria

Inclusion Criteria:

1. Voluntarily sign the informed consent form

2. Currently receiving IPI-926 while participating in an Infinity-sponsored IPI-926 study. Note: For blinded studies, patient's treatment assignment must be unblinded according to the instructions in the original protocol to confirm they are receiving IPI-926.

3. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.

4. Documented response or stable disease, as defined in the original protocol, at the time of entry to the extension study.

5. Willingness and ability to continue IPI-926 dispensation and follow-up procedures at the current investigational site.

6. Willingness and ability to comply with scheduled visits, treatment plans, and laboratory tests and other study procedures.

7. Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum or urine pregnancy test prior to treatment. All WCBP, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study.

Exclusion Criteria:

1. Discontinued IPI-926 or withdrew informed consent to participate in original Infinity-sponsored IPI-926 study.

2. Require addition of or change to a new concomitant therapy to adequately treat the malignancy under study.